The Use of Tamoxifen to Improve Height Potential in Short Pubertal Boys

  title={The Use of Tamoxifen to Improve Height Potential in Short Pubertal Boys},
  author={Nerissa C. Kreher and Erica A. Eugster and R Ravi Shankar},
  pages={1513 - 1515}
A retrospective chart review of 7 pubertal boys who were treated with tamoxifen was conducted to determine the effects of this therapy on skeletal maturation and predicted adult height. Tamoxifen significantly decreased the rate of skeletal maturation and increased the predicted adult height without negative effects on sexual maturation. Additional evaluation of this therapy is now required to determine if the increase in predicted adult height results in a clinically significant increase in… 

Tables from this paper

Long-term Follow-up of Tamoxifen Treatment in Adolescents with Gynecomastia

Ten pubertal boys treated with tamoxifen for gynecomastia for more than 3 months were evaluated after 2.5-7 years (mean 4.6 years) to determine the side effects of this therapy. We assessed the

Idiopathic short stature: management and growth hormone treatment.

  • J. WitE. Reiter P. Cohen
  • Medicine
    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • 2008

The effect of tamoxifen on pubertal bone development in adolescents with pubertal gynecomastia

Assessment of the effects of tamoxifen on bone mineral density (BMD) and skeletal maturation when used for pubertal gynecomastia concluded that when Pubertal bone development is concerned, tamoxIFen is safe for the treatment of pubertals gyne comastia as neither bone mineralization nor growth potential was affected.

Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review

Tamoxifen may be effective for the treatment of pubertal gynecomastia, and it seems safe to use, and Randomized controlled studies are necessary to confirm this indication.

Hormonal Treatment of Idiopathic Short Stature

  • E. Reiter
  • Medicine
    Hormone Research in Paediatrics
  • 2007
Long-term data are needed to assess the behavioral consequences, if any, of GH treatment for children with idiopathic short stature and the use of aromatase inhibitors to slow estrogen-mediated skeletal maturation is a new treatment modality.

Aromatase inhibitors for short stature in male children and adolescents.

BACKGROUND As a result of the essential role of oestrogens in epiphyseal closure, aromatase inhibitors have been trialled as an intervention to improve height outcomes in male children and

Growth Hormone Therapy for Short Stature: Is the Benefit Worth the Burden?

Analysis of therapeutic value of rhGH therapy for short stature requires not only examination of effects on adult height but also of the rationale for intervention itself, whether improved height actually leads to better psychosocial outcomes, and how benefits compare to risks and costs.

Induction and Maintenance of Amenorrhea in Transmasculine and Nonbinary Adolescents

The physiology of the normal menstrual cycle and the hormonal influences on the endometrium are reviewed, and options for the treatment of persistent bleeding for people both already on testosterone and for those who are either not ready for or who do not desire testosterone are explored.

Oestrogen receptors and linear bone growth

It is concluded that SERMs potentially could offer new possibilities to modulate bone growth by specifically targeting different oestrogen receptors within the growth plate.



Tamoxifen treatment for pubertal gynecomastia

Tamoxifen treatment is relatively non-toxic, may be beneficial and it should be considered for pubertal gynecomastia, and the dose was increased in three patients due to poor response.

Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial.

It is indicated that delaying puberty with LHRH-A in GHD children during treatment with GH increases final height, and this delay in BA maturation produced a significant gain in final height in the group treated with GH+LHRH, which reached - 1.3 +/- 0.5 SD score.

A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom).

The cardinal features of this syndrome are a consequence of P450arom deficiency, and the striking delay in bone age at 14 2/12 yr supports the notion that estrogens, in contrast to androgens, are the major sex steroid driving skeletal maturation during puberty.

Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man.

Disruption of the estrogen receptor in humans need not be lethal and is important for bone maturation and mineralization in men as well as women.

Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children's Research Hospital.

Tamoxifen and carboplatin chemotherapy did not result in a significant number of objective responses in children with low-grade gliomas, and the progression-free survival is similar to that of other published series.

Juvenile fibromatosis: hormonal receptors.

Radiographic Atlas of Skeletal Development of the Hand and Wrist

The Brush Foundation studies on human growth and development, begun in 1931 and terminated in 1942, have been intensively reviewed and studied by Dr. Greulich and Miss Pyle in the formulation of this